Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ROS1-positive Non-Small Cell Lung Cancer (NSCLC)”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Not applicableAvailableNCT06797362
What this trial is testing

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Who this might be right for
Non Small Cell Lung CancerROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Nuvalent Inc.
Early research (Phase 1)Study completedNCT03607188
What this trial is testing

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Not applicableNot Yet RecruitingNCT06694129
What this trial is testing

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerROS1 Gene RearrangementResistance+1 more
National Cancer Center, China 40
Testing effectiveness (Phase 2)UnknownNCT03972189
What this trial is testing

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 111
Not applicableNo Longer AvailableNCT03178071
What this trial is testing

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Who this might be right for
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Pfizer
Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Not applicableNot Yet RecruitingNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Not applicableActive Not RecruitingNCT06678555
What this trial is testing

Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 35
Not applicableNo Longer AvailableNCT02824094
What this trial is testing

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Who this might be right for
NeoplasmsCarcinoma, Non-Small-Cell Lung
Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT05765877
What this trial is testing

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer(NSCLC)
Pingping Song 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT04621188
What this trial is testing

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 54
Not applicableNo Longer AvailableNCT06841874
What this trial is testing

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

Who this might be right for
Lung NeoplasmsRespiratory Tract NeoplasmsThoracic Neoplasms+8 more
Nuvation Bio Inc.
Testing effectiveness (Phase 2)Study completedNCT01945021
What this trial is testing

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerROS1 Proto OncogeneCrizotinib
Pfizer 129
Testing effectiveness (Phase 2)UnknownNCT03389815
What this trial is testing

A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients

Who this might be right for
Advanced Solid Tumor, Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 48
Testing effectiveness (Phase 2)Study completedNCT01970865
What this trial is testing

PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Who this might be right for
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Pfizer 364
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Post-approval studies (Phase 4)Active Not RecruitingNCT05144997
What this trial is testing

Lorlatinib Continuation Study

Who this might be right for
Non-Small-Cell Lung CancerNSCLC
Pfizer 76
Testing effectiveness (Phase 2)Looking for participantsNCT04237805
What this trial is testing

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Advanced CancerAdvanced Solid TumorLung Cancer, Nonsmall Cell
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 280
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Load More Results